Arun Azad, MBBS, PhD, FRACP, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, talks on plasma cell-free DNA profiling of PI3K/Akt pathway aberrations in two multi-institutional independent metastatic castration-resistant prostate cancer (mCRPC) cohorts. Dr Azad discusses the emergence of circulating tumor DNA (ctDNA) as a source of molecular profiling and outlines the significance and implications of PTEN loss. This interview took place during the 2021 Genitourinary Cancers Symposium.
PI3K/Akt pathway aberrations in mCRPC
Теги
Speaker: Arun AzadInstitution: Peter MacCallum Cancer CentreEvent: GU Cancers 2021Format: InterviewSubject: Genitourinary CancerSubject: Prostate CancerField: Disease BiologyPI3K/Akt pathwayplasma cell-free DNA profilinggenomicsmetastatic castration-resistant prostate cancermCRPCPTENandrogen receptor pathwayAR pathway inhibitorsAkt pathway inhibitorsPI3K inhibitors
